Computational Insights into the Drug Repurposing and Synergism of FDA-approved Influenza Drugs Binding with SARS-CoV-2 Protease against COVID-19
Computational Insights into the Drug Repurposing and Synergism of FDA-approved Influenza Drugs Binding with SARS-CoV-2 Protease against COVID-19
S. Parveen,R. Alnoman,A. Bayazeed,Alaa M. Alqahtani
2020 · DOI: 10.12691/AJMR-8-3-3
7 Citations
TLDR
The findings of this study can facilitate rational drug design targeting the SARS-Cov-2 main protease using FDA-approved influenza drugs as an effective inhibitor against COVID-19.